The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to <1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. The Secondary Objective is to confirm the tolerability of this regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of Nexrutine®. Molecular response is defined as changes in the molecular pathways.

No new, undiagnosed bone pain or has a negative bone scan. (within 2 months of consent) If there is no bone pain, then a bone scan is not required.

Exclusion Criteria:

Has documented metastatic disease.

Has received a prior chemotherapy or androgen ablation.

Has received prior immunotherapy.

Has been previously treated with Strontium, Samarium, other systemic radioisotopes or radiation therapy.

Has diagnosis of congestive heart failure

Currently taking anticoagulation medications, i.e., coumadin or heparin. Over the counter aspirin and ibuprofen are allowed.

Is receiving any other investigational agents for cancer.

Has a history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of prostate cancer.

Has a serious intercurrent illness with a life expectancy of less than 5 years.

Has a concomitant medical, psychological, or social circumstance, which would interfere with compliance with the protocol treatment and follow-up.

Use of any herbal or alternative regimens, which may have antineoplastic or hormonal activity (including but not limited to finasteride, dutasteride, Saw Palmetto, PC-SPES, shark cartilage, etc), is prohibited while receiving study treatment.

Clinical stage T3 or T4 and PSA >10 ng/ml and Gleason > 8.

Patient is to receive adjuvant androgen ablation with the radiation.

EKG which shows a baseline QTc > 450 msec or ischemic changes. For ischemic changes, patient will be eligible if evaluated and cleared by internal medicine.

Previous history of drug-induced QTc prolongation and/or concurrent treatment with medications that are known to produce or are suspected of QT prolongation.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01705652

Locations

United States, Texas

The University of Texas Health Science Center at San Antonio, study site: ALM VA Hospital

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

The University of Texas Health Science Center at San Antonio

Investigators

Principal Investigator:

Gregory P. Swanson, MD

The University of Texas Health Science Center at San Antonio

Principal Investigator:

William E. Jones, III, MD

The University of Texas Health Science Center at San Antonio and ALM VA Hospital

More Information

No publications provided

Responsible Party:

Gregory P. Swanson, MD, Clinical Professor, The University of Texas Health Science Center at San Antonio